Form 8-K · Current report
Labcorp 8-K, filed Aug 14, 2026
- Filed
- CIK
- 0000920148
- Accession no.
- 0000920148-26-000182
Summary
Labcorp Holdings Inc. executive Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International effective September 4, 2026, while Brian J. Caveney will become Executive Vice President and President, Biopharma Laboratory Services and retain his role as Chief Medical and Scientific Officer effective September 1, 2026, overseeing the Early Development Research Laboratories and Central Laboratories businesses.
Key points
- Megan D. Bailey notified Labcorp Holdings Inc. on August 11, 2026, of her resignation as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026.
- Brian J. Caveney currently serves as Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer.
- Effective September 1, 2026, Caveney will become Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, responsible for Early Development Research Laboratories and Central Laboratories.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026. Effective September 1, 2026, Brian J. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.